Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).MASH is a severe liver disease characterized by fat buildup and inflammation in the liver, which can lead to cirrhosis and liver cancer if untreated.The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg ...